Physician profile
Suraj Modi
NPI 1144756305
$2,010.30
in general payments reported to CMS, 2019-2025
27 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.64 · 2023: $455 · 2024: $1,033 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Education: $40.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.87 |
| Education | $40.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.96 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $193.22 | 2024 | Qelbree |
| Novo Nordisk INC | $181.62 | 2023-2025 | Rybelsus, Ozempic |
| Corium, LLC | $143.86 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $130.03 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $100.42 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $80.72 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $76.11 | 2023-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $53.78 | 2024 | |
| Exact Sciences Corporation | $53.11 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $51.73 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $50.28 | 2024 | Spravato |
| Noven Therapeutics, LLC | $48.05 | 2024-2025 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.39 | 2024-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $47.01 | 2024 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.86 | 2025 | |
| Lilly USA, LLC | $30.18 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $29.45 | 2025 | Otezla, Repatha |
| Aimmune Therapeutics, INC. | $23.97 | 2025 | Zenpep |
| Collegium Pharmaceutical, INC. | $23.83 | 2025 | Jornay Pm |
| Pfizer INC. | $17.03 | 2023 | |
| Hikma Pharmaceuticals USA | $16.29 | 2024 | Ryaltris |
| Sanofi Pasteur INC. | $15.30 | 2023 | |
| Daiichi Sankyo INC. | $15.29 | 2024 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $15.10 | 2025 | Airsupra |
| Almatica Pharma LLC | $14.92 | 2025 | Loreev Xr |
| Inspire Medical Systems, INC. | $13.79 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraj Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.